Key facts
| Firm | Meds for Vets |
|---|---|
| FEI / inspection ID | 3003829708 |
| Inspection end date | February 21, 2025 |
| Citation count | 12 |
Citations explained
Observation 1 — Procedures designed to prevent microbiological contamination of drug products purporting to be
Procedures designed to prevent microbiological contamination of drug products purporting to be sterile did not include validation of the aseptic and sterilization process. Specifically, 1)The air pressure gauge used to perform post (b) (4) (b) (4) ) of all (b) (4) have never been calibrated. The air pressure gauge is used to ensure the (b) (4) of the (b) (4) . (b) (4) for both human and animal drug products, are tested using this air pressure gauge. Since 12/16/2024, your firm has dispensed approximately (b) (4) sterile drug product units that have been aseptically (b) (4) 2)The (b) (4) , model(b) (4) used to (b) (4) sterilize compounded drug products, and components used for sterile compounded drug products has not been qualified. The effectiveness of the (b) (4) sterilization cycle has not been initially validated or verified annually. In addition, your firm does not use external probes to monitor each load cycle and biological indicators are not always used during.
Observation 2 — Use of ingredients not intended for pharmaceutical use in sterile drug production
Use of ingredients not intended for pharmaceutical use in sterile drug production. Specifically, your firm uses (b) (4) for irrigation in the production of sterile human and animal injectable drug products. For example, according to your firm’s logged formula worksheet (compounding record) for Apomorphine Hcl 6mg/ml – Nst Injection (animal drug product), lot 917, beyond use date 01/17/2025, your firm used (b) (4) for irrigation, lot (b) (4)to produce this product. ■ (b) (4) of this sterile drug product was dispensed on 01/06/2025. According to your firm’s logged formula worksheet (compounding record) for Tirzepatide/B12 (methyl) 10mg/0.5mg/ml -Injection (human drug product) lot 2316, your firm used to produce (b) (4) of this sterile drug product. (b) (4) (b) (4) for irrigation used is labeled “not for ■-- (b) (4) of (b) (4) for irrigation, lot (b) (4) of this product was dispensed on 01/30/2025 -. The injection”. Your firm lacks scientific justification why
Observation 3 — The final and intermediate containers/closures used for drug product intended to be
The final and intermediate containers/closures used for drug product intended to be sterile have not been sterilized or depyrogenated. Specifically, Your firm has failed to validate the cleaning, sterilization, and/or (b) (4) process for drug products and drug components used in sterile compounding operations. For example, 1) Your firm uses an unvalidated sterilization cycle for non-sterile vials purchased. In addition, your firm does not (b) (4) these vials before use. These vials are used a final container for all sterile compounded injectable drug products. Your firm does not verify that vials and/or components used for sterile drug products are pyrogen free. On 02/13/2025, I observed sterile vials staged on a cart shelf, in the ISO7 classified room, open and exposed to the environment. Sterile vials are staged in the ISO7 classified room for immediate use. 2) Reusable glassware such as but not limited to beakers, used for weighing and mixing drug products are not sterilized or (b) (4) after cleaning..
Observation 4 — Equipment used in the manufacture, processing, packing or holding of drug products
Equipment used in the manufacture, processing, packing or holding of drug products is not of adequate size to facilitate operations for its intended use.
Observation 5 — Biological indicators were not used to verify the adequacy of the sterilization
Biological indicators were not used to verify the adequacy of the sterilization cycle. Specifically, 1) On 02/13/2025, I observed the compound drug product Natamycin 4% - Nst Eye Drop, Lot 2465, date manufactured (b) (4) , beyond use date 03/13/2025 complete a (b) (4) sterilization cycle in the (b) (4) , model (b) (4) without the use of a Biological Indicator. 75ml of Natamycin 4% - Nst Eye Drop, Lot 2465, date made 02/13/2025, beyond use date 03/13/202, was dispensed on 02/14/2025. 2) On 02/17/2025, I observed a tray of clear vials and stoppers complete a (b) (4) sterilization cycle in in the (b) (4) , model (b) (4) without the use of a Biological Indicator. These components are purported to be sterile and are used as final container/closures for sterile drug products. 3) The number of biological - indicators used and incubated when certain drug products or components are exposed to (b) (4) sterilization or (b) (4) sterilization is.
Observation 6 — Personnel were observed touching equipment or other surfaces located outside of the
Personnel were observed touching equipment or other surfaces located outside of the ISO 5 area with gloved hands and then proceeding with aseptic processing without changing or sanitizing gloves. Specifically, 1) On 02/12/2025 during the production of NAD+ 200mg/ml injectable, lot 2395, I observed your firm's sterile compounding technician touching multiple surfaces such as but not limited a garbage bag, door handles and the knobs of the (b) (4) (b) (4) while wearing sterile gloves. Your sterile compounding technician returned to aseptically filling the compounded drug product without changing gloves. 10ml of this sterile human drug product was dispensed on 02/14/2025. 2) On 02/13/2025 during the production of EDTA 1% eyedrops, lot 2488, made date (b) (4) , beyond use date 03/30/2025 and on 02/17/2025 during the production of T rzepatide/B12 25mg/.05mg/ml Inj, lot 2565, beyond use date 03/31/2025, I observe - i d your firm's sterile compounding technician touching multiple surfaces such as but limited to a bottle of.
Observation 7 — Use of non-sterile cleaning pads in the ISO 5 area and classified
Use of non-sterile cleaning pads in the ISO 5 area and classified areas. Specifically, your firm uses non-sterile cleaning wipes to clean the surfaces your of ISO5 classified Laminar Flow Hoods where sterile injectable drug products are filled. In addition, the non-sterile cleaning wipes are stored open in your ISO7 classified buffer room and your ISO8 classified ante-room.
Observation 8 — Failure to conduct media fills that closely simulate aseptic production operations under
Failure to conduct media fills that closely simulate aseptic production operations under the worst-case, most-challenging, and stressful conditions. Specifically, Media fills performed by your firm with each of the technicians/pharmacists that works in the ISO5 classified area do not closely simulate actual production conditions or cover worst-case or most challenging conditions. The media fills your firm performs has the technician/pharmacist filling media into (b) (4) vials and media into (b) (4) control vials. In routine production, your firm fills various size vials (b) (4) ). Batch sizes are typically in excess of (b) (4) and can be as many as (b) (4)units.
Observation 9 — The quality control unit lacks authority to fully investigate errors that have
The quality control unit lacks authority to fully investigate errors that have occurred. Specifically, according to your firm’s most recent room/hood certification, dated 08/22/2024, conducted by (b) (4) , your firm’s ISO7 classified room, used for sterile compounding of hazardous drugs, failed pressure differential testing; your firm’s ISO5 classified laminar flow hood (Equipment
Observation 10 — Smoke studies were inadequately performed under dynamic conditions
Smoke studies were inadequately performed under dynamic conditions. Specifically, a review of your firm’s smoke studies dated 02/24/2024 showed insufficient smoke being used to determine unidirectional airflow within your ISO5 classified Laminar Flow Hoods. Your firm’s ISO5 classified Laminar Flow Hoods are used to aseptically fill both hazardous and non-hazardous drug products.
Observation 11 — Testing and release of drug product for distribution do not include appropriate
Testing and release of drug product for distribution do not include appropriate laboratory determination of satisfactory conformance to the identity and strength of each active ingredient prior to release. Specifically, your firm does not conduct routine testing for potency (assay) for all drug products produced by your firm including both sterile and non-sterile.
Observation 12 — There is no written testing program designed to assess the stability characteristics
There is no written testing program designed to assess the stability characteristics of drug products.
What a Form 483 means
A Form FDA 483 is issued at the close of an FDA facility inspection to list conditions an investigator observed that may violate the Federal Food, Drug, and Cosmetic Act or its implementing regulations. It reflects the investigator's professional judgment at that point in time and is not a final agency determination, an enforcement action, or proof that a violation occurred. Firms are expected to respond in writing, typically within 15 business days, describing the corrective and preventive actions they plan to take. FDA reviews that response, along with any follow-up evidence, before deciding what happens next. Many 483s are resolved through corrective action alone. When FDA judges a firm's response inadequate, or when the underlying conditions are serious enough, the observations documented here can lead to a Warning Letter or further regulatory action. This page presents the observations exactly as recorded on the FDA-issued document; always confirm citation language against the original record before relying on it.
Meds for Vets’s FDA history
Argus HQ has recorded 1 total FDA action tied to Meds for Vets: 0 warning letters, 0 recalls, 0 approval records, and 1 Form 483 inspection citation.
Frequently asked questions
- Does this Form 483 mean Meds for Vets violated the law?
- No. A Form 483 documents an investigator's observations only. FDA reviews the firm's written response and any corrective actions taken before deciding whether further action is warranted, and many 483s are closed without additional enforcement once a firm shows adequate correction.
- What happens after a Form 483 is issued?
- The firm typically has 15 business days to submit a written response describing planned corrections. FDA reviews that response, and unresolved or serious findings can lead to a Warning Letter, import alert, or other enforcement action, though many 483s are resolved without further FDA action.
- Has Meds for Vets had other FDA inspection citations?
- This is the only FDA action Argus HQ has on file for Meds for Vets so far. Argus ingests new FDA records daily.
- What is the FEI / inspection ID for this Form 483?
- FEI / inspection ID: 3003829708.
See if this 483 escalates to a warning letter — before your auditor asks.
Free weekly briefing tracks every FDA inspection outcome.
Related enforcement actions
Full FDA history for Meds for VetsCompiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder
Cite this record
Reusing this data in reporting or research? Here’s a ready-made citation.
Argus HQ Research (2025). Form 483 Record: Meds for Vets, February 21, 2025 — 12 Citations. Digital Empire LLC. Retrieved from https://argushq.ai/483/fda-483-meds-for-vets-2025-02-21-3003829708
"Form 483 Record: Meds for Vets, February 21, 2025 — 12 Citations." Argus HQ Research, Digital Empire LLC, 2025, argushq.ai/483/fda-483-meds-for-vets-2025-02-21-3003829708.
Argus HQ Research. "Form 483 Record: Meds for Vets, February 21, 2025 — 12 Citations." Digital Empire LLC. Accessed July 15, 2026. https://argushq.ai/483/fda-483-meds-for-vets-2025-02-21-3003829708.
@misc{argushq_argushq_ai_483_fda_483_meds_for_vets_2025_02_21_3003829708_2025,
title = {Form 483 Record: Meds for Vets, February 21, 2025 — 12 Citations},
author = {{Argus HQ Research}},
year = {2025},
publisher = {Digital Empire LLC},
url = {https://argushq.ai/483/fda-483-meds-for-vets-2025-02-21-3003829708},
note = {Accessed: July 15, 2026}
}